BTIG Adjusts Prometheus Biosciences' Price Target to $74 From $62, Maintains Buy Rating
BTIG Adjusts Prometheus Biosciences' Price Target to $74 From $62, Maintains Buy Rating
BTIG將普羅米修斯生物科學的目標股價從62美元調整至74美元,維持買入評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊